Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box

home / between-the-lines / third-line-treatment-of-her2-positive-advanced-breast-cancer-from-no-standard-to-a-pandora-s-box

In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.

EP. 1: Third-Line Treatment Data for HER2+ Advanced Breast Cancer

Sara Hurvitz, MD;Steven Vogl, MD

August 12th 2021

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, highlight key concepts from a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

EP. 2: HER2+ Advanced Breast Cancer: Selecting Third-Line Therapy

Sara Hurvitz, MD;Steven Vogl, MD

August 13th 2021

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

EP. 3: Experts Discuss Third-line Treatment Options for HER2-Positive Advanced Breast Cancer

ONCOLOGY Staff

November 8th 2021

“We’ve been spoiled by 2 extraordinary experiences [in this setting]. Both tucatinib and trastuzumab deruxtecan are much better than anything we’ve had since we got pertuzumab for first-line therapy.” —SARA A. HURVITZ, MD, FACP